Subscribe

Erlotinib (Tarceva) Treatment | Risk Factors for Gastrointestinal Perforation

Purpose:

To identify risk factors for gastrointestinal perforation in a patient being treated with erlotinib (Tarceva).

Specialty:

Hematology Oncology
Gastroenterology

Objective:

risk factors, adverse effects

ICD-10:

T45.1

Description:

Erlotinib (Tarceva) is a human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Some patients who have received it have had gastrointestinal perforations, with fatalities reported.

To read more or access our algorithms and calculators, please log in or register.

RECENT TWEETS

medal descover
medal iphone